{"id":{"repo_id":"glasgow","oai_identifier":"oai:theses.gla.ac.uk:76846"},"canonical_url":"https://search.ndltd.org/etd/glasgow/oai:theses.gla.ac.uk:76846","repository":{"repo_id":"glasgow","name":"University of Glasgow","base_url":"https://theses.gla.ac.uk/cgi/oai2"},"display":{"title":"Ablative Treatment With Autologous Bone Marrow Transplantation for Acute Myeloid Leukaemia","abstract":"Improvements have taken place in recent years, in the treatment of acute myeloid leukaemia(AML) with a steady increase in the proportion of patients entering complete remission. There has been less progress in devising appropriate post-remission therapy, with the result that there is a continuous risk of disease recurrence with most patients dying from their disease within five years. For a minority of patients a combination of chemotherapy and total body irradiation, designed to be ablative to the bone marrow, supported by bone marrow transplantation from an HLA matched sibling donor has proved effective, being capable of curing half the patients, but having the probability of eradicating leukaemia in approximately 80% of patients.","abstract_html":"Improvements have taken place in recent years, in the treatment of acute myeloid leukaemia(AML) with a steady increase in the proportion of patients entering complete remission. There has been less progress in devising appropriate post-remission therapy, with the result that there is a continuous risk of disease recurrence with most patients dying from their disease within five years. For a minority of patients a combination of chemotherapy and total body irradiation, designed to be ablative to the bone marrow, supported by bone marrow transplantation from an HLA matched sibling donor has proved effective, being capable of curing half the patients, but having the probability of eradicating leukaemia in approximately 80% of patients.","abstract_has_math":false,"creators":["Burnett, Alan Kenneth"],"institution":"University of Glasgow","degree_name":null,"degree_level":"MD","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":1988,"date_issued":"1988","date_published":"1988","updated_at":"2026-11-19T08:31:29Z","subjects":[],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"https://theses.gla.ac.uk/76846/1/10970894.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://theses.gla.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Atheses.gla.ac.uk%3A76846","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:creator","label":"Author","values":["Burnett, Alan Kenneth"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["1988"]},{"key":"dc:date.issued","label":"Date","values":["1988"]},{"key":"dc:publisher.commercial","label":"Dc Publisher Commercial","values":["ProQuest Dissertations & Theses,"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["Department of Haematology."]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Glasgow"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["https://theses.gla.ac.uk/76846/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["MD"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://theses.gla.ac.uk/76846/1/10970894.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Improvements have taken place in recent years, in the treatment of acute myeloid leukaemia(AML) with a steady increase in the proportion of patients entering complete remission. There has been less progress in devising appropriate post-remission therapy, with the result that there is a continuous risk of disease recurrence with most patients dying from their disease within five years. For a minority of patients a combination of chemotherapy and total body irradiation, designed to be ablative to the bone marrow, supported by bone marrow transplantation from an HLA matched sibling donor has proved effective, being capable of curing half the patients, but having the probability of eradicating leukaemia in approximately 80% of patients."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public"]},{"key":"dc:title","label":"Title","values":["Ablative Treatment With Autologous Bone Marrow Transplantation for Acute Myeloid Leukaemia"]}]}],"canonical_facts":{"dc:creator":["Burnett, Alan Kenneth"],"dc:date":["1988"],"dc:date.issued":["1988"],"dc:description.abstract":["Improvements have taken place in recent years, in the treatment of acute myeloid leukaemia(AML) with a steady increase in the proportion of patients entering complete remission. There has been less progress in devising appropriate post-remission therapy, with the result that there is a continuous risk of disease recurrence with most patients dying from their disease within five years. For a minority of patients a combination of chemotherapy and total body irradiation, designed to be ablative to the bone marrow, supported by bone marrow transplantation from an HLA matched sibling donor has proved effective, being capable of curing half the patients, but having the probability of eradicating leukaemia in approximately 80% of patients."],"dc:format":["application/pdf"],"dc:identifier.uri":["https://theses.gla.ac.uk/76846/1/10970894.pdf"],"dc:language":["en"],"dc:publisher.commercial":["ProQuest Dissertations & Theses,"],"dc:publisher.department":["Department of Haematology."],"dc:publisher.institution":["University of Glasgow"],"dc:relation.isreferencedby":["https://theses.gla.ac.uk/76846/"],"dcterms:accessrights":["public"],"dc:title":["Ablative Treatment With Autologous Bone Marrow Transplantation for Acute Myeloid Leukaemia"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["MD"]},"updated_at":"2026-11-19T08:31:29Z"}